Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$26.91 USD
-0.26 (-0.96%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $26.91 0.00 (0.00%) 7:46 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 41 - 60 ( 195 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Advantage Ensifentrine; Competitor Data Underscores Ensi''s Broad Potential
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
New Drug Application Timing Unchanged; 2022 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
As The Dust Settles -- Sifting Through The Biotech Carnage, We See Opportunity
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q4/FY22 Financials; Ensifentrine/COPD NDA Submission in Q2:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Building on Last Year''s Momentum; a 2023 Top Pick
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine Shines in ENHANCE-1 Study, As Expected; Raising PT to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Seeing Double: Ph3 ENHANCE-2 Results Replicate in Ph3 ENHANCE-1
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Enhancing Expectations Ahead of the Topline ENHANCE-1 Results Around YE:22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Second Pivotal Trial Readout Approaching; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q3 Financials; All Eyes on ENHANCE-1 Data for Ensifentrine COPD Around YE:22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine KOL Call Highlights; $150M Debt Financing
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
ENHANCE-2 Analyses Raise Our Confidence in Ensifentrine; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R